Transition Therapeutics
Toronto
About Transition Therapeutics
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $41.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2014)
- Ticker: nasdaq:TTHI
- Website: transitiontherapeutics.com
- Phone: 416-260-7770
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/transition-therapeutics-2076707 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.